We track 2 organisations in this sector across 1+ countries.
2 entries.
Co-founder and CEO of SOPHiA GENETICS, the Lausanne-based clinical AI company he co-founded in 2011 as an EPFL spin-out. Camblong led SOPHiA GENETICS for over a decade from a university genomics project to a Nasdaq IPO in July 2021, raising $228M and building a federated clinical AI network used by over 780 healthcare institutions in 70 countries for genomic analysis in oncology and rare disease diagnostics.
SOPHiA GENETICS is a Lausanne-based health-tech company founded in 2011 by Jurgi Camblong and Pierre Hutter as an EPFL spin-out. The company built a clinical AI platform — SOPHiA DDM — that enables hospital and laboratory networks to decode genomic data for oncology, rare disease, and pharmacogenomics applications. Its platform standardises and accelerates genomic analysis across a federated network of more than 780 healthcare institutions in 70 countries, turning each new clinical dataset into a contribution to a collectively smarter system. SOPHiA GENETICS listed on Nasdaq in July 2021, raising $228M, and is backed by Salesforce Ventures and Generation Investment Management. The company represents the EPFL ecosystem's capacity to produce globally significant clinical technology at scale.